Brief: Resonance Health Says acquisition of TrialsWest Group
April 2 (Reuters) - Resonance Health Ltd RHT.AX :
* TRIALSWEST IS EXPECTED TO CONTRIBUTE A$2 MILLION IN
REVENUE AND
A$0.67 MILLION IN EBITDA ON ANNUALISED BASIS
* ACQUISITION OF TRIALSWEST GROUP
* CONTRACTED TO ACQUIRE 100% OF TRIALSWEST PTY LTD
* WILL PAY UPFRONT CASH CONSIDERATION OF A$4 MILLION UNDER
TERMS
OF SHARE SALE AGREEMENT
* FURTHER A$4 MILLION MAY BE PAYABLE TO TRIALSWEST VENDORS
UNDER
EARNOUT ARRANGEMENT SUBJECT TO CONDITIONS
Further company coverage: RHT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resonance Health
See all newsAustralia's Resonance Health jumps on FY26 forecast hike
Brief: Resonance Health Expects FY26 Underlying EBITDA A$2.6 Mln
Brief: Resonance Health Says Martin Blake Retires As Chair
Brief: Resonance Health Contracted For Clinical Drug Trial Worth A$13.775 Mln
Brief: Resonance Seeks Trading Halt Pending Announcement On Execution Of Contract For Services For Clinical Trial By Pharma Co